Continued RVU120 treatment study for current participants
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial is for people who are already in a RVU120 study and have been receiving the drug for at least 5 cycles. It allows you to keep getting RVU120 if you are benefiting from it and don't have other treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are already in a RVU120 study and have taken the drug for at least 5 cycles.
- You are currently benefiting from RVU120 and your doctor agrees you should continue.
- You do not have access to any other approved cancer treatment that works for you.
- You agree to use birth control (if needed) as per local rules.
- You sign a consent form to join this rollover study.
- You agree not to donate blood during the study and for 6.5 months after your last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, RVU120, combined with venetoclax for people with AML that has come back or not responded to treatment. It may be an option if you've already tried venetoclax with another drug and it didn't work.
This early-phase study tests a combination of ruxolitinib with venetoclax, with or without azacitidine, for adults whose acute myeloid leukemia (AML) has come back or does not respond to treatment. It may help by stopping cancer cells from growing and improving blood counts, with the exact plan guided by the study arm you’re assigned to.
This is a “rollover” study for people who were already taking a Roche (or Genentech) cancer study medicine. It checks whether continuing the same study treatment (when commercial options aren’t available) can keep helping you.
This trial tests a new treatment called RN1201 for blood cancers like multiple myeloma, certain leukemias, and lymphomas that have not improved with standard treatments or have returned. The treatment targets specific markers on cancer cells (CD19 and BCMA) and may offer a new option for patients who have run out of standard choices.
This trial tests a new drug, INCA033989, alone or with ruxolitinib for people with certain blood cancers called myeloproliferative neoplasms (MPNs). It may help those with a specific genetic change (CALR mutation) who have not had success with other treatments.
This trial tests a new type of immune cell therapy (CART123) alone or with a drug called ruxolitinib for children and young adults with AML that has come back or not responded to standard treatment. The goal is to see if this combination can help destroy leukemia cells.
Hear when a new High Risk Myelodysplastic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.